Diagnostic

About Calviri

Calviri is a private, clinical-stage biotech leveraging a novel discovery about a fundamental molecular characteristic of tumors to develop early cancer detection diagnostics and off-the-shelf vaccines. The company's core strategy is a 'One Health' approach, initially targeting the significant unmet need in canine cancer with its first commercial product, StageOne Plus, a multi-cancer diagnostic test, and advancing preventative (VACCS) and therapeutic vaccine trials in dogs. This veterinary focus provides a faster development and regulatory pathway, aiming to generate proof-of-concept, revenue, and data to de-risk subsequent human applications. Calviri is backed by venture funding and grants, positioning it to potentially disrupt oncology by shifting the paradigm from late-stage treatment to early detection and prevention.

About Calviri

Calviri is a private, clinical-stage biotech leveraging a novel discovery about a fundamental molecular characteristic of tumors to develop early cancer detection diagnostics and off-the-shelf vaccines. The company's core strategy is a 'One Health' approach, initially targeting the significant unmet need in canine cancer with its first commercial product, StageOne Plus, a multi-cancer diagnostic test, and advancing preventative (VACCS) and therapeutic vaccine trials in dogs. This veterinary focus provides a faster development and regulatory pathway, aiming to generate proof-of-concept, revenue, and data to de-risk subsequent human applications. Calviri is backed by venture funding and grants, positioning it to potentially disrupt oncology by shifting the paradigm from late-stage treatment to early detection and prevention.

Therapeutic Areas